Fluid Medical

Company Overview

Snapshot

Founded in September 2020 by Oren Shuster, Fluid Medical operates with 1–10 employees. The company has secured funding across one disclosed round from one investor, Israel MedicUp, to advance its algorithm-based technology for pancreatic cyst diagnosis.

Business overview

Fluid Medical is developing an algorithm-based technology for the examination of pancreatic cysts, aiming to provide accurate clinical diagnoses within minutes. Its solution focuses on immediate and precise cyst fluid classification based on physical properties of the fluid sample. The company's technology is designed to reduce unnecessary exploratory surgeries for non-cancerous cysts, lower hospital costs, mitigate patient risks, and enable prompt drug treatment for malignant cysts, thereby improving patient outcomes. Fluid Medical operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Test Diagnostics & Screening, serving healthcare providers, laboratories, and pharmaceutical companies.

Company Intelligence Q&A

Who founded Fluid Medical?

Fluid Medical was co-founded by Oren Shuster in September 2020.

What is Fluid Medical's primary focus?

Fluid Medical focuses on developing algorithm-based technology for the rapid and accurate diagnosis of pancreatic cysts, aiming to improve patient outcomes and reduce unnecessary medical procedures.

What problem does Fluid Medical's technology address?

Fluid Medical's technology addresses the need for accurate and immediate classification of pancreatic cyst fluid, which can help reduce unnecessary exploratory surgeries for non-cancerous cysts and enable timely treatment for malignant ones.

Which sector does Fluid Medical operate in?

Fluid Medical operates within the Health Tech & Life Sciences sector, with a specific focus on Pharma & Medical Biotechnology and Test Diagnostics & Screening.

What is the current stage of Fluid Medical's product development?

Fluid Medical's product is currently in the R&D stage, focusing on the development of its algorithm-based technology for pancreatic cyst diagnosis.